Literature DB >> 10068598

Class II HLA alleles and hepatitis B virus persistence in African Americans.

C L Thio1, M Carrington, D Marti, S J O'Brien, D Vlahov, K E Nelson, J Astemborski, D L Thomas.   

Abstract

Persistence of hepatitis B virus (HBV) infection is likely due to the interplay of the virus and host immune response. Given its critical role in antigen presentation, allelic differences in the HLA complex may affect HBV persistence. In a prospectively followed African American cohort, molecular class I and class II HLA typing was done on 31 subjects with persistent HBV infection and 60 controls who cleared the infection. HBV persistence was significantly associated with two class II alleles, DQA1 *0501 (odds ratio [OR], 2.6; P=.05) and DQB1 *0301 (OR, 3.9; P=.01), the two-locus haplotype consisting of these same two alleles (OR, 3; P=. 005) and the three-locus haplotype, DQA1 *0501, DQB1 *0301, and DRB1 *1102 (OR, 10.7; P=.01). In addition, HBV persistence was associated with class II allelic homozygosity. Several class I associations with persistence were also noted but were not statistically significant after correction for multiple comparisons. These results underscore the importance of the class II-mediated immune response in recovery from HBV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068598     DOI: 10.1086/314684

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

1.  Polymorphisms of microsomal triglyceride transfer protein in different hepatitis B virus-infected patients.

Authors:  Zhi-Tao Yang; Xin-Xin Zhang; Xiao-Fei Kong; Dong-Hua Zhang; Shen-Ying Zhang; Jie-Hong Jiang; Qi-Ming Gong; Gen-Di Jin; Zhi-Meng Lu
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

2.  C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection.

Authors:  M Tevfik Dorak; Gbolahan O Folayan; Santosh Niwas; Dirk J van Leeuwen; Leland J Yee; Jianming Tang; Richard A Kaslow
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection.

Authors:  Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

4.  Host susceptibility to persistent hepatitis B virus infection.

Authors:  Ying-Li He; Ying-Ren Zhao; Shu-Lin Zhang; Shu-Mei Lin
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

5.  Correlation of HLA-DQB1 gene polymorphism of Xinjiang Uygur with outcome of HBV infection.

Authors:  Yongping Zhang; Fengcong Zhao; Liu Lan; Zhao Qin; Liang Jun
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 6.  Hepatitis E and pregnancy: understanding the pathogenesis.

Authors:  Udayakumar Navaneethan; Mayar Al Mohajer; Mohamed T Shata
Journal:  Liver Int       Date:  2008-07-25       Impact factor: 5.828

7.  Human leukocyte antigen (HLA)-B, DRB1, and DQB1 allotypes associated with disease and protection of trachoma endemic villagers.

Authors:  Muneer Abbas; Linda D Bobo; Yu-Hsiang Hsieh; Noureddine Berka; Georgia Dunston; George E Bonney; Victor Apprey; Thomas C Quinn; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-29       Impact factor: 4.799

Review 8.  A rationalized approach to the treatment of patients infected with hepatitis B.

Authors:  Natravis R Cox; Keyur Patel; Hans L Tillmann
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

9.  Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B.

Authors:  Ye-Gui Jiang; Yu-Ming Wang; Tong-Hua Liu; Jun Liu
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

10.  Selective suppression of NF-kBp65 in hepatitis virus-infected pregnant women manifesting severe liver damage and high mortality.

Authors:  Bhupesh K Prusty; Suresh Hedau; Ajay Singh; Premasis Kar; Bhudev C Das
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.